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Abstract Alternations of copper (Cu) and zinc (Zn) status in
diabetes have received a great attention. Tauroursodeoxycholic
acid (TUDCA) and 4-phenylbutyric acid (PBA) could alleviate
the increased endoplasmic reticulum (ER) stress and prevent
insulin resistance. This study aimed to investigate the effect of
TUDCA and PBA on metabolism of Cu and Zn in diabetic
mice model. Diabetes was induced by streptozotocin in FVB
mice treated with and without TUDCA and PBA. Determina-
tion of Cu and Zn in tissues and serum by acid digestion was
followed by ICP-MS. The renal and serum Cu levels were
significantly higher, while the hepatic Cu and Zn levels were
significantly decreased in the diabetic mice at 2 weeks and
2 months after diabetes onset. The increase of cardiac Cu to-
gether with the decrease of muscular Zn was found in the dia-
betic mice only at 2 months. Cu levels were positively correlat-
ed with Zn in the heart, liver, kidney, muscle, spleen, and serum
of diabetic and control mice at both 2 weeks and 2 months.
Both PBA and TUDCA reduced serum Zn, and PBA reduced
hepatic Cu to normal levels in the diabetic mice at two time
points, while PBA normalized serum Cu in the diabetic mice
only at 2 months. PBA increased hepatic Zn to normal levels in
the diabetic mice at 2 weeks, while it partially increased hepatic
Zn in the same group at 2 months. Therefore, maintaining ho-
meostasis of Cu and Zn by TUDCA and PBA in diabetes needs
to be received with special attention.
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Introduction
Diabetes mellitus (DM) has become one of the most severe
endocrine metabolic disorders in the world. Diabetes damages
multiple organs to induce serious complications such as dia-
betic retinopathy, neuropathy, and nephropathy that can result
in the disability and mortality for diabetic patients [1]. Exces-
sive caloric intake and high-energy diet quality are major driv-
ing forces behind escalating diabetes and the appearance of
epidemics worldwide [2]. As an essential component of the
daily diet intake, trace elements are important for the occur-
rence and progression of diabetes. Alternations in trace ele-
ment status and increased oxidative stress in diabetes may
contribute to insulin resistance and the development of diabe-
tes and diabetic complications [3, 4]. On the other hand, pro-
gression of diabetes may also lead to perturbation in trace
element metabolism and homeostasis [5].
Cu and Zn are prooxidants, playing critical roles in metal-
catalyzed formation of free radicals. In the presence of copper
ions, a hydroxyl radical, which is the most powerful reactive
oxygen species (ROS), can be produced via the Fenton or the
metal-catalyzed Haber-Weiss reaction [6]. These two chemi-
cal reactions appear to account for most of the hydroxyl rad-
ical production in biological systems and explain, at least in
part, why Cu produces oxidative stress and ROS-induced in-
jury in cells. Cu and Zn also act as structural and catalytic
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components of some metalloenzymes [5]. For example, Cu is
necessary for the catalytic activity of Cu/Zn superoxide dismut-
ase (SOD) [5], extracellular superoxide dismutase (EC-SOD)
[7], cytochrome c oxidase (COX) [8], and ceruloplasmin/
ferroxidase [9]. Zn acts as an antioxidant by protecting the
sulfhydryl groups of proteins and enzymes against free radical
damage in the body [10]. Abnormal Cu metabolism is associ-
ated with human and experimental diabetes. Cu deficiency can
cause neurodegeneration [11] and hematological and cardiovas-
cular disorders [12], whereas Cu overloadmay be accompanied
by hepatic and neurological diseases [13, 14]. Recently, we
found the serum Cu level was significantly higher in the pa-
tients with impaired fasting glucose, impaired glucose toler-
ance, and type 2 diabetes, compared to control subjects [15].
The contribution of alternations in the homeostasis ions of these
metals on the occurrence and progression of diabetes is still
being discussed. The significance of variable concentrations
of these trace metals in different organs of streptozotocin
(STZ)-induced diabetic mice is discussed.
Chemical or pharmaceutical chaperones, such as
tauroursodeoxycholic acid (TUDCA) and 4-phenylbutyric ac-
id (PBA), could alleviate the increased endoplasmic reticulum
(ER) stress [16]. Recently, several papers focus on the rela-
tionship between the chaperones and calcium. A study indi-
cates both PBA and TUDCA inhibit the reduction in mito-
chondrial calcium and decrease in mitochondrial reactive ox-
ygen species (mROS) despite ongoing hypoxia in pulmonary
artery smooth muscle cells of rats [16]. TUDCA significantly
increases hepatic calcium content and serum calcium concen-
tration after ischemia-reperfusion in rat [17]. TUDCA mark-
edly prevents aortic valve calcification in both rabbit and
mouse models of aortic valve calcification [18]. There was
no much information for the effect of chaperones on metabo-
lism of Cu and Zn in diabetic mice model.
This study aimed to investigate the effect of TUDCA and
PBA on metabolism of Cu and Zn in diabetic mice model. We
supposed that TUDCA and PBA could be effective in themain-
tenance of homeostasis of Cu and Zn in diabetes. In the present
study, we measured the changes of Cu and Zn concentrations in
the heart, liver, kidney, muscle, spleen, and serum in type 1
diabetic mice treated with and without chaperones.
Materials and Methods
Animal Models
Male Friend virus B (FVB) mice, 8 weeks of age, purchased
from Vital River Laboratories (Beijing, China), were housed
in the Experimental Animal Center of College of Basic Med-
ical Sciences of Jilin University at 22 °Cwith a 12-h light/dark
cycle and free access to standard rodent chow and tap water.
All animal procedures were approved by the Institutional
Ethics Committee of the First Hospital of Jilin University.
The mice were randomly divided into six groups (n = 14 in
each group), namely, nondiabetic control mice (CON), diabet-
ic mice (DM), diabetic mice treated with PBA (PBA +DM) or
TUDCA (TUDCA+DM), and nondiabetic control mice treat-
ed with PBA (PBA) or TUDCA (TUDCA). Type 1 diabetic
mice were induced by intraperitoneal injection of multiple
low-dose STZ (40 mg/kg body weight daily for 5 days; Sigma
Chemical Co., St. Louis, MO, USA) dissolved in a sodium
citrate buffer (pH 4.5). Five days after the last injection of
STZ, whole blood obtained from each mouse’s tail vein was
used for glucose monitoring with the use of a glucometer
(Bayer HealthCare, Mishawaka, IN, USA). STZ-treated mice
with whole-blood glucose levels higher than 12 mmol/L were
considered diabetic. Two days before the last injection of STZ,
acclimation was started with daily phosphate-buffered saline
(PBS) administration. The groups used for PBA (Merck
KGaA, Hohenbrunn, Germany) treatments served 100 μL
PBS twice per day (8 am and 8 pm) by gavage and the groups
used for TUDCA (Calbiochem, La Jolla, CA, USA) treat-
ments received intraperitoneal injection of 100 μl PBS at the
same time points (8 am–8 pm) for 3 days. Three days later, at
8 am, blood samples were collected from the tail vein for
measurement of glucose levels and treatments were initiated
with the vehicle or the drugs. This time point was taken as day
zero. PBA was administered two times a day in two divided
doses (500 mg/kg for 8 am and 8 pm, total 1 g/kg/day) by oral
gavage. TUDCA was applied intraperitoneally at the same
time points (250 mg/kg for 8 am and 8 pm, total 500 mg/kg/
day). Controls for PBA, received the same volume of vehicle
by gavage and controls for TUDCA-treated group received
the same volume of vehicle by intraperitoneal injection. Body
weight and blood glucose levels were measured regularly.
Animals from each group were sacrificed 2 weeks and
2 months after the administration of PBA or TUDCA (n = 7
in each time point of each group). The animals were anesthe-
tized with 2 % sodium pentobarbital (30 mg/kg, intraperito-
neal) and were sacrificed by cardiac puncture. Heart, liver,
kidney, spleen, and soleus muscles were harvested and stored
at −80 °C. Blood samples through the retro-orbital plexus
were taken into special metal-free tubes for analysis of labo-
ratory parameters. After blood centrifugation, serum was
aliquoted into metal-free Eppendorf test tubes, shock-frozen,
and stored at −80 °C for later analysis.
Determination of Cu and Zn by Acid Digestion Followed
by ICP-MS
Preweighed pieces of tissue samples (approximately 0.5–1 g
of tissue) from the above experiments were digested separate-
ly in 1 mL nitric acid in a 10-mL glass vial at room tempera-
ture and then heated to 110 °C for 8 h to facilitate digestion. A
volume of 4 mL deionized water was added to each vial to
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increase the volume to 5 mL. The resulting clear liquid was
used for analysis. Cu and Zn concentrations were determined
by Agilent Technologies 7700 Series ICP-MS equipment
(Agilent Technologies, Santa Clara, CA, USA). The instru-
ment was tuned on a daily basis to ensure optimisation. Rf
Power was 1550 W and nebulizer gas flow rate was kept at
1.05 L/min. A heating program appropriated to each type of
sample was applied. Cu and Zn concentrations were expressed
as micrograms per liter wet tissue.
Other Measurements
Laboratory indices including glycosylated serum protein
(GSP), blood urea nitrogen (BUN), creatinine (Cre), uric
acid (UA), total cholesterol (CHO), triglyceride (TG),
high-density lipoprotein (HDL), and low-density lipo-
protein cholesterol (LDL) levels were performed by
Hitachi 7600-010 Clinical Chemistry Analyzer (Hitachi,
Tokyo, Japan) using standard methodology from the
blood samples, which were obtained at the time of
sacrifice.
Statistical Analysis
Continuous variables were expressed as mean ± SE.
Student’s t test was used for comparisons between
groups. Spearman rank correlation analysis was used
to evaluate the correlations between serum Cu and Zn
level as a continuous variable and laboratory parame-
ters. All reported p values were two-sided, and values
of p < 0.05 were considered statistically significant.
Statistical analyses were performed using SPSS 17.0.
Results
Baseline Characteristics
Baseline characteristics of type 1 diabetic mice were summa-
rized in Table 1. Decreased body weight and increased blood
glucose were seen in the diabetic mice at both 2 weeks and
2 months after the onset of diabetes. However, TUDCA or
PBA inhibited the trends of body weight and blood glucose
in the diabetic mice, although the body weight and blood
glucose could not restore normal level. Both GSP and BUN
levels were significantly increased in the diabetic mice at
2 months and TUDCA or PBA did not show any effect on
them. Cre was significantly increased in the diabetic mice at
2 months, but not diabetic mice treated with PBA. TUDCA
reduced CHO and LDL to normal levels in the diabetic mice at
2 months. TUDCA and PBA partially suppressed the increase
of TG and LDL in the diabetic mice at 2 months, respectively.
Compared to control, the serum of Cu level was significantly
higher in the diabetic mice at both 2 weeks and 2 months after
the onset of diabetes. PBA reduced Cu to normal levels in the
diabetic mice at 2 months. There were no significant differ-
ences among all groups for the following serum laboratory
parameters: UA and HDL.
Analysis of Cu and Zn in the Heart, Liver, Kidney,Muscle,
Spleen, and Serum of Type 1 Diabetic Mice Treated With
and Without Chaperones
Compared to respective control, the renal Cu level was signif-
icantly higher in the diabetic mice treated with and without
chaperones both at 2 weeks and 2 months, while the cardiac
Cu level was significantly lower and muscular Zn was signif-
icantly higher in the same groups only at 2 months. PBA
increased hepatic Cu to normal levels in the diabetic mice both
at 2 weeks and 2 months, while both PBA and TUDCA in-
creased serum Zn, and PBA normalized serum Cu in the dia-
betic mice only at 2 months. PBA increased hepatic Zn to
normal levels in the diabetic mice at 2 weeks, while it partially
increased hepatic Zn in the same group at 2 months. There
were no significant differences of Cu levels in the muscle and
spleen, Zn levels in the heart, kidney, and spleen among all
groups. The levels of Cu and Zn in the heart, liver, kidney,
muscle, spleen, and serum of type 1 diabetic mice model are
presented in Table 1 and Fig. 1.
Associations Between Cu and ZnLevel in the Heart, Liver,
Kidney, Muscle, Spleen, and Serum of Type 1 Diabetic
Mice Treated With and Without Chaperones
We analyzed associations between Cu and Zn in tissues and
the serum of all groups (Tables 2 and 3 and Fig. 2). Overall,
Cu levels were positively correlated with zinc in the heart,
liver, kidney, muscle, spleen, and serum of all groups both at
2 weeks and 2 months except the spleen of diabetic mice
treated with TUDCA at 2 weeks. The correlation curve be-
tween serum Cu and serum Zn in all groups is presented in
Fig. 2.
Discussion
In the present study, decreased body weight and in-
creased blood glucose were seen in the diabetic mice
at both 2 weeks and 2 months after the onset of dia-
betes. These results are in accordance with the results
previously reported after STZ treatment of diabetic
mice [19]. The levels of GSP, BUN, Cre, CHO, TG,
and LDL were significantly increased in the diabetic
mice at 2 months, consistent with the previous findings
[20, 21].
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Cu and Zn in Tissues and Serum
Diabetes results in several metabolic changes, including alter-
ations in the transport, distribution, excretion, and accumula-
tion of metals [22]. To our knowledge, this is the first study to
systematically analyze Cu and Zn in the heart, liver, kidney,
muscle, spleen, and serum of type 1 diabetic mice. In the
present study, the renal and serum Cu levels were significantly
higher, while the hepatic Cu and Zn levels were significantly
decreased in the diabetic mice at 2 weeks and 2 months. The
decrease of cardiac Cu together with the increase of muscular
Zn was found in the diabetic mice only at 2 months. There
Fig. 1 Levels of Cu in the heart,
liver, kidney, muscle, spleen, and
serum of type 1 diabetic mice
model. Levels of Cu in the heart
(a), liver (b), kidney (c), muscle
(d), spleen (e), and serum (f) in
2 weeks and 2 months after the
administration of PBA or
TUDCA. Data are presented as
mean ± SE, n = 7 in all groups.
CON nondiabetic control group,
DM diabetic mice group, PBA +
DM group of diabetic mice treated
with PBA, TUDCA + DM group
of diabetic mice treated with
TUDCA, PBA group of
nondiabetic control mice treated
with PBA, TUDCA group of
nondiabetic control mice treated
with TUDCA
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were no significant differences of Cu levels in the muscle and
spleen, Zn levels in the heart, kidney, spleen, and serum
among all groups. The present study indicated an imbalance
in amounts of Cu and Zn in STZ-diabetic mice compared to
their levels in healthy subjects.
ROS are known to preferably attack lipids and lead to ab-
normalities in lipid metabolism in diabetes, while diabetic
dyslipidemia induces oxidative load [23]. Free radical produc-
tion is considered as one of the major mechanisms responsible
for the toxicity of Cu [24]. Excessive tissue accumulation of
redox-active Cu ions can be cytotoxic, in particular because
perturbations in metal homeostasis result in an array of cellu-
lar disturbances characterized by oxidative stress and in-
creased free radical production [6]. The increased serum and
renal Cu may increase oxidative stress and subsequent inflam-
mation, leading to the insulin resistance and development of
diabetes. These findings may contribute to explain the role of
impaired ion metabolism of Cu and Zn in the progression of
diabetic oxidative complications. In the present study, the
amounts of Cu and Zn were not consistent in tissues and
serum at different time points. The blood usually represents
a small, but rapidly mobilizable pool of the metal ion. In
contrast, tissues, such as the liver, represent a large storage
pool of the metal, which exchange only very slowly with the
pool of metal in the bloodstream [22]. Our results imply per-
turbations in homeostasis of Cu and Zn in tissues and serum of
STZ-induced diabetic mice may be involved in disturbances
of oxidative balance. Therefore, these findings may contribute
to explain the role of impaired ion metabolism of some ele-
ments in the progression of diabetic oxidative complications.
Associations Between Cu and Zn Level in Tissues
and Serum
We analyzed associations between Cu and Zn in tissues and
serum of all groups. Interestingly, Cu levels were positively
correlated with Zn in the heart, liver, kidney, muscle, spleen,
and serum of all groups both at two time points except the
Table 2 Associations between Cu and Zn level in the heart, liver, kidney, muscle, spleen, and serum of 2-week mice
Cu
CON PBA TUDCA PBA + DM TUDCA + DM DM
r p r p r p r p r p r p
H-Zn 0.865 0.012* 0.955 0.001* 0.821 0.023* 0.857 0.014* 0.847 0.016* 0.857 0.014*
L-Zn 0.847 0.016* 0.893 0.007* 0.857 0.014* 0.811 0.027* 0.919 0.003* 0.893 0.007*
K-Zn 0.821 0.023* 0.811 0.027* 0.857 0.014* 0.901 0.006* 0.847 0.016* 0.857 0.014*
M-Zn 0.901 0.006* 0.786 0.036* 0.893 0.007* 0.964 <0.001* 0.847 0.016* 0.893 0.007*
P-Zn 0.821 0.023* 0.964 <0.001* 0.821 0.023* 0.955 0.001* 0.464 0.294 0.937 0.002*
S-Zn 0.857 0.014* 0.964 <0.001* 0.964 <0.001* 0.929 0.003* 0.964 <0.001* 0.857 0.014*
Abbreviations’ spellings are same as the description for Table 1
*p < 0.05 for the association
Table 3 Associations between Cu and Zn level in the heart, liver, kidney, muscle, spleen, and serum of 2-month mice
Cu
CON PBA TUDCA PBA + DM TUDCA + DM DM
r p r p r p r p r p r p
H-Zn 0.893 0.007* 0.893 0.007* 0.821 0.023* 0.929 0.003* 0.893 0.007* 0.893 0.007*
L-Zn 0.857 0.014* 0.929 0.003* 0.929 0.003* 0.893 0.007* 0.821 0.023* 0.857 0.014*
K-Zn 0.937 0.002* 0.821 0.023* 0.821 0.023* 0.929 0.003* 0.964 <0.001* 0.544 <0.001*
M-Zn 0.786 0.036* 0.893 0.007* 0.821 0.023* 0.857 0.014* 0.893 0.007* 0.857 0.014*
P-Zn 0.847 0.016* 0.893 0.007* 0.883 0.008* 0.964 <0.001* 0.955 0.001* 0.929 0.003*
S-Zn 0.857 0.014* 0.937 0.002* 0.918 0.004* 0.929 0.003* 0.786 0.036* 0.929 0.003*
Abbreviations’ spellings are same as the description for Table 1
*p < 0.05 for the association
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spleen of diabetic mice treated with TUDCA at 2 weeks. In
our previous study, serum Cu levels were positively correlated
with serum Zn in control subjects and the patients with type 1
diabetes [15]. These results indicated that Cu levels were pos-
itively associated with Zn in tissues and serum in health and
diabetes of human and mice model, which implied Cu and Zn
may have regulatory effects on each other. Further clinical and
animal investigations with larger numbers of cases are needed.
Effect of TUDCA and PBA on Metabolism of Copper
and Zinc
TUDCA is a bile acid existed in human bile at low concentra-
tion and has a very good safety profile. It has been used for
centuries in traditional Chinese medicine (isolated from the
dried bile of adult black bears) in the treatment of a variety
of ailments. TUDCA also has been used widely in clinical
applications in the Western World for treatment of biliary
and liver diseases [25]. PBA has been approved by the U.S.
Food and Drug Administration for clinical use in urea-cycle
disorders as an ammonia scavenger and has been in clinical
trials for the treatment of other diseases such as thalassemia
and cystic fibrosis [26]. Both TUDCA and PBA have been
attributed to antiapoptotic, anti-inflammatory, antioxidative,
and immunomodulation effects [18, 25, 27]. A few studies
indicate that TUDCA and PBA enhance the adaptive capacity
of ER and prevent insulin resistance [25, 26].
In the present study, there was a small but statistically sig-
nificant increase in body weight and a decrease in blood glu-
cose in the TUDCA- or PBA-treated groups. When adminis-
tered to diabetic mice, TUDCA and PBA exhibited a potent
antidiabetic activity [26]. Recently, several papers focus on
the relationship between the chaperones and calcium
[16–18]. However, there has been no much information for
the effect of chaperones on metabolism of copper and zinc in
diabetic mice model. In the present study, both PBA and
TUDCA increased serum Zn, and PBA increased hepatic Cu
to normal levels in the diabetic mice at two time points, while
PBA normalized serum Cu in the diabetic mice only at
2 months. PBA increased hepatic Zn to normal levels in the
diabetic mice at 2 weeks, while it partially increased hepatic
Zn in the same group at 2 months. Our results confirmed the
chaperones extended a protective action in STZ-induced dia-
betes. To our knowledge, this is the first report to study the
effects of TUDCA and PBA on the mineral distribution of
tissues in type 1 diabetic mice.
There was no much information for the mechanism of
chaperones on metabolism of copper and zinc in diabetic mice
model. Recently, a study indicates both PBA and TUDCA
inhibit the reduction in mitochondrial calcium and decrease
in mROS [16]. We hypothesize that chaperones maintain ho-
meostasis of Cu and Zn at least via their antioxidative effects.
The detailed mechanism of chaperones maintaining homeo-
stasis of trace elements in diabetes remains unclear and in
need of further exploration.
There are several limitations of this work. First, because of
the little number of mice in each group, there still remains un-
certainty as to the results in this research. Second, because of not
detecting laboratory indices of ROS, we could not evaluate the
association between ROS and trace elements in tissues and
serum of type 1 diabetic mice. Third, we did not investigate
themechanism of chaperones onmetabolism of copper and zinc
in diabetic mice model in detail. A well-designed study to ad-
dress these limitations may be necessary in the future to indicate
BA
r=0.456, P<0.01 r=0.310, P<0.05
Fig. 2 Correlation between serum Cu and serum Zn in type 1 diabetic mice model. Correlations between serum Cu and serum Zn in 2 weeks (r = 0.456,
p < 0.01, a) and 2 months (r = 0.310, p < 0.05, b) after the administration of PBA or TUDCA
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the effect of chaperones on metabolism of copper and zinc in
clinical and animal investigations with larger numbers of cases.
Conclusions
Alternations of Cu and Zn status in diabetes have received
great attention. TUDCA and PBA could alleviate the in-
creased ER stress and prevent insulin resistance. This is the
first study to systematically analyze the effects of TUDCA
and PBA on Cu and Zn distributions in tissues and serum in
STZ-induced diabetic mice. We found the following: (1) Cu
and Zn levels were imbalanced in the heart, liver, kidney,
muscle, and serum of STZ-diabetic mice compared to their
levels in healthy subjects; (2) Cu levels were positively corre-
lated with Zn in the heart, liver, kidney, muscle, spleen, and
serum of diabetic and control mice at both 2 weeks and
2 months after the onset of diabetes; (3) both PBA and
TUDCA increased serum Zn, and PBA increased hepatic Cu
to normal levels in the diabetic mice at two time points, while
PBA normalized serum Cu in the diabetic mice only at
2 months. PBA increased hepatic Zn to normal levels in the
diabetic mice at 2 weeks, while it partially increased hepatic
Zn in the same group at 2 months. Therefore, maintaining
homeostasis of Cu and Zn by TUDCA and PBA in diabetes
needs to be received with special attention. We suggest that
chemical chaperones in general, and PBA and TUDCA in
particular, may warrant clinical investigation as regulators
for imbalance of Cu and Zn in diabetes.
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